Most coverage of Eli Lilly (NYSE: LLY) focuses on one number: how much weight its drugs help people take off.
The question that matters more for the rest of 2026 is a different one
How many people can now access those drugs in the first place? That shift, from a science story to a drug access story, is the reason I think the stock has room to climb before the year is out. A weight loss pill changes who Eli Lilly can reach In April, the FDA approved Foundayo (orforglipron), the first GLP-1 pill for weight management that a person can take at any time of day with no food or water restrictions.
That last detail carries more weight than it seems. Injectable treatments need refrigeration, needles, and a comfort with self-injection that keeps a lot of would-be patients on the sidelines. A daily pill strips away those barriers.